Cargando…

One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials

The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Forssten, Sofia D., Ouwehand, Arthur C., Griffin, Síle M., Patterson, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840472/
https://www.ncbi.nlm.nih.gov/pubmed/35276927
http://dx.doi.org/10.3390/nu14030568
_version_ 1784650627964469248
author Forssten, Sofia D.
Ouwehand, Arthur C.
Griffin, Síle M.
Patterson, Elaine
author_facet Forssten, Sofia D.
Ouwehand, Arthur C.
Griffin, Síle M.
Patterson, Elaine
author_sort Forssten, Sofia D.
collection PubMed
description The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspects of health by changing the environment within the gut, and several lines of evidence now indicate a beneficial effect of probiotics on mental and brain health. Such evidence has prompted the arrival of a new term to the world of biotics research: psychobiotics, defined as any exogenous influence whose effect on mental health is bacterially mediated. Several taxonomic changes in the gut microbiota have been reported in neurodevelopmental disorders, mood disorders such as anxiety and depression, and neurodegenerative disorders such as Alzheimer’s disease. While clinical evidence supporting the role of the gut microbiota in mental and brain health, and indeed demonstrating the beneficial effects of probiotics is rapidly accumulating, most of the evidence to date has emerged from preclinical studies employing different animal models. The purpose of this review is to focus on the role of probiotics and the microbiota–gut–brain axis in relation to mood disorders and to review the current translational challenges from preclinical to clinical research.
format Online
Article
Text
id pubmed-8840472
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88404722022-02-13 One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials Forssten, Sofia D. Ouwehand, Arthur C. Griffin, Síle M. Patterson, Elaine Nutrients Review The microbiota–gut–brain axis is a bidirectional communication pathway that enables the gut microbiota to communicate with the brain through direct and indirect signaling pathways to influence brain physiology, function, and even behavior. Research has shown that probiotics can improve several aspects of health by changing the environment within the gut, and several lines of evidence now indicate a beneficial effect of probiotics on mental and brain health. Such evidence has prompted the arrival of a new term to the world of biotics research: psychobiotics, defined as any exogenous influence whose effect on mental health is bacterially mediated. Several taxonomic changes in the gut microbiota have been reported in neurodevelopmental disorders, mood disorders such as anxiety and depression, and neurodegenerative disorders such as Alzheimer’s disease. While clinical evidence supporting the role of the gut microbiota in mental and brain health, and indeed demonstrating the beneficial effects of probiotics is rapidly accumulating, most of the evidence to date has emerged from preclinical studies employing different animal models. The purpose of this review is to focus on the role of probiotics and the microbiota–gut–brain axis in relation to mood disorders and to review the current translational challenges from preclinical to clinical research. MDPI 2022-01-27 /pmc/articles/PMC8840472/ /pubmed/35276927 http://dx.doi.org/10.3390/nu14030568 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Forssten, Sofia D.
Ouwehand, Arthur C.
Griffin, Síle M.
Patterson, Elaine
One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title_full One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title_fullStr One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title_full_unstemmed One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title_short One Giant Leap from Mouse to Man: The Microbiota–Gut–Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials
title_sort one giant leap from mouse to man: the microbiota–gut–brain axis in mood disorders and translational challenges moving towards human clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840472/
https://www.ncbi.nlm.nih.gov/pubmed/35276927
http://dx.doi.org/10.3390/nu14030568
work_keys_str_mv AT forsstensofiad onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials
AT ouwehandarthurc onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials
AT griffinsilem onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials
AT pattersonelaine onegiantleapfrommousetomanthemicrobiotagutbrainaxisinmooddisordersandtranslationalchallengesmovingtowardshumanclinicaltrials